Halozyme Therapeutics HALO Net debt
Discontinued — last reported Q1 '26
Net debt at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's net debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's net debt?
- Halozyme Therapeutics (HALO) reported net debt of $1.87B in Q1 2026.
- How has Halozyme Therapeutics's net debt changed year-over-year?
- Halozyme Therapeutics's net debt increased by 37.1% year-over-year, from $1.36B to $1.87B.
- What is the long-term trend for Halozyme Therapeutics's net debt?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's net debt has grown at a 51.7% compound annual growth rate (CAGR), from $253.89M to $2.04B.
- What does net debt mean?
- Debt left over after using all the company's cash to pay it down.
- How do you interpret net debt?
- A negative value means net cash — more cash than debt, a position of strength. The numerator of net-debt/EBITDA, the most common leverage yardstick.
- How does net debt compare across companies?
- Most informative as net-debt/EBITDA; cash-rich balance sheets can show large total debt yet little or negative net debt.